Healthcare Industry News: uterine cancer
News Release - February 19, 2008
CytoCore Launches SoftPAP(TM) Cervical Cell Collector in SpainCHICAGO--(HSMN NewsFeed)--CytoCore Inc. (OTCBB:CYOE ), the biopharmaceutical research and medical device company for early detection and treatment of reproductive-tract cancers, announced today its first order and shipment of SoftPAP™ cell collectors to Palex Medical SA.
Palex Medical SA, a leading medical equipment and solutions distributor to the Spanish hospital market based in Sant Cugat del Vallès (Barcelona), Spain will be the second company in Europe to launch CytoCore’s SoftPAP™ cervical cell collector, a device designed to enhance patient comfort and safety while improving the quality of cervical cell specimens for Pap testing. With Palex as distributor, Spain is the second country in Europe to receive the SoftPAP Collector.
"We are very pleased to be introducing this important new product to our Spanish medical market," says Xavier Carbonell, Deputy President of Palex Medical. "The Collector’s combination of improved patient comfort, ease of use and more reliable test results represents a significant advance in women's health. We are very interested in CytoCore and its product line. There are several CytoCore products under development that we believe represent opportunities for our markets and clients, and we are looking forward to expanding our relationship with CytoCore."
SoftPAP is designed to collect a full 360 degree specimen from both the cervical canal and the outer surface of the cervix simultaneously resulting in a more complete and comprehensive specimen for Pap testing. Clinical studies have shown that SoftPAP collects a better quality specimen while reducing adverse events, primarily bleeding and spotting, by 95%.
“SoftPAP is a vast improvement over the current method which involves specimen collection using a wooden or plastic spatula and cervical brush,” says Dick Domanik, Ph.D., President and COO of CytoCore.
About Palex Medical, SA
Palex is a leading company in the hospital sector whose priority goal is to understand and satisfy the needs of health professionals and managers. To achieve this goal, it provides advanced, efficient hospital solutions with products, systems, technologies and health services grounded on knowledge and experience, and also by establishing distribution agreements with leading international manufacturers. http://www.palexmedical.com/english/index.php
About CytoCore Inc.
CytoCore develops cost-effective cancer screening systems, which can be utilized in a laboratory or at the point-of-care, to assist in the early detection of cervical, endometrial, and other cancers. The CytoCore Solutions™ System is being developed to provide medical practitioners with highly accurate, low-cost, cervical and uterine cancer screening systems that can be seamlessly integrated into existing medical models. More information is available at: www.CytoCoreInc.com.
Certain statements in this release are forward-looking. These statements are based on CytoCore's current expectations and involve many risks and uncertainties, such as the company's inability to obtain sufficient financing, the possibility that clinical trials will not substantiate CytoCore's expectations with respect to the CytoCore Solutions™ System, and other factors set forth in reports and documents filed by CytoCore with the Securities and Exchange Commission. Actual results may differ materially from CytoCore's current expectation depending upon a number of factors affecting the Company's business. These factors include, among others, risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Annual Report on Form 10-K for the year ended December 31, 2006. Except as expressly required by law, CytoCore undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.